HomeCompareTNFA vs STAG

TNFA vs STAG: Dividend Comparison 2026

TNFA yields 38.46% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TNFA wins by $194.8K in total portfolio value
10 years
TNFA
TNFA
● Live price
38.46%
Share price
$5.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$213.1K
Annual income
$34,859.06
Full TNFA calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — TNFA vs STAG

📍 TNFA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTNFASTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TNFA + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TNFA pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TNFA
Annual income on $10K today (after 15% tax)
$3,269.23/yr
After 10yr DRIP, annual income (after tax)
$29,630.20/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, TNFA beats the other by $29,237.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TNFA + STAG for your $10,000?

TNFA: 50%STAG: 50%
100% STAG50/50100% TNFA
Portfolio after 10yr
$115.7K
Annual income
$17,660.64/yr
Blended yield
15.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

TNFA
No analyst data
Altman Z
-11.6
Piotroski
0/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TNFA buys
0
STAG buys
0
No recent congressional trades found for TNFA or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTNFASTAG
Forward yield38.46%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0.3%
Portfolio after 10y$213.1K$18.3K
Annual income after 10y$34,859.06$462.22
Total dividends collected$158.5K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: TNFA vs STAG ($10,000, DRIP)

YearTNFA PortfolioTNFA Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$14,546$3,846.15$10,665$345.09+$3.9KTNFA
2$20,793$5,228.67$11,364$357.70+$9.4KTNFA
3$29,234$6,985.18$12,098$370.43+$17.1KTNFA
4$40,458$9,178.25$12,869$383.28+$27.6KTNFA
5$55,162$11,871.34$13,677$396.23+$41.5KTNFA
6$74,150$15,126.76$14,524$409.27+$59.6KTNFA
7$98,344$19,003.53$15,411$422.41+$82.9KTNFA
8$128,783$23,555.24$16,339$435.61+$112.4KTNFA
9$166,626$28,828.07$17,311$448.89+$149.3KTNFA
10$213,149$34,859.06$18,327$462.22+$194.8KTNFA

TNFA vs STAG: Complete Analysis 2026

TNFAStock

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Full TNFA Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this TNFA vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TNFA vs SCHDTNFA vs JEPITNFA vs OTNFA vs KOTNFA vs MAINTNFA vs PLDTNFA vs EQRTNFA vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.